haloperidol has been researched along with pirenzepine in 237 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.42) | 18.7374 |
| 1990's | 71 (29.96) | 18.2507 |
| 2000's | 154 (64.98) | 29.6817 |
| 2010's | 11 (4.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Altenbach, RJ; Brioni, JD; Carr, TL; Chandran, P; Cowart, MD; Esbenshade, TA; Honore, P; Hsieh, GC; Lewis, LG; Liu, H; Manelli, AM; Marsh, KC; Milicic, I; Miller, TR; Strakhova, MI; Vortherms, TA; Wakefield, BD; Wetter, JM; Witte, DG | 1 |
| Hayashi, S; Kato, A; Mizuno, K; Morita, A; Nakata, E; Ohashi, K; Yamamura, K | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Anzini, M; Brogi, S; Butini, S; Campiani, G; Cappelli, A; Caselli, G; Castriconi, F; Gemma, S; Giordani, A; Giorgi, G; Giuliani, G; Lanza, M; Letari, O; Makovec, F; Manini, M; Mennuni, L; Valenti, S | 1 |
| Belyakov, S; Dambrova, M; Kazoka, H; Kuznecovs, J; Lebedev, A; Liepinsh, E; Mishnev, A; Orlova, N; Ponomaryov, Y; Vavers, E; Veinberg, G; Vikainis, S; Vilskersts, R; Vorona, M; Zvejniece, L | 1 |
| Bienkowski, P; Bucki, A; Jaśkowska, J; Kazek, G; Kowalski, P; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Mitka, K; Pawłowski, M; Siwek, A; Wasik, A; Wesołowska, A | 1 |
| Bienkowski, P; Bucki, A; Jastrzębska-Więsek, M; Kazek, G; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Partyka, A; Pawłowski, M; Siwek, A; Śniecikowska, J; Wasik, A; Wesołowska, A | 1 |
| Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E | 1 |
| Filipek, B; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pańczyk, K; Pękala, E; Rapacz, A; Słoczyńska, K; Waszkielewicz, AM; Żelaszczyk, D; Żesławska, E | 1 |
| Bucki, A; Gryboś, A; Głuch-Lutwin, M; Jastrzębska-Więsek, M; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Partyka, A; Pawłowski, M; Pytka, K; Siwek, A; Śniecikowska, J; Wesołowska, A; Więckowski, K | 1 |
| Cubeddu, LX; James, MK | 1 |
| Benvenga, MJ; Leander, JD | 1 |
| Takaki, T; Tanaka, M; Yamada, S; Yokoo, H | 1 |
| Kameyama, T; Kobayashi, T; Ukai, M | 1 |
| Beasley, CM; Hamilton, S; Sanger, T; Satterlee, W; Tollefson, G; Tran, P | 1 |
| Busatto, GF; Costa, DC; Ell, PJ; Kerwin, RW; Nohria, V; Pilowsky, LS; Sharma, T; Sigmundsson, T; Taylor, M | 1 |
| Beasley, CM; Graffeo, KA; Krueger, JA; Street, JS; Tamura, RN; Thieme, ME; Tollefson, GD; Tran, PV | 1 |
| Sanger, TM; Tollefson, GD | 2 |
| Gleason, SD; Shannon, HE | 1 |
| Beasley, CM; Beuzen, JN; Blin, O; Crawford, AM; Dellva, MA; Hamilton, SH; Tollefson, GD; Tran, PV | 1 |
| Beasley, CM; Dellva, MA; Kiesler, GM; Potvin, JH; Tollefson, GD; Tran, PV | 1 |
| Borsini, F; Cerutti, M; Fodritto, F; Monferini, E; Volonté, M | 1 |
| Beasley, CM; Tollefson, GD; Tran, PV | 2 |
| Nemeroff, CB | 1 |
| Glazer, WM; Johnstone, BM | 1 |
| Casey, DE | 1 |
| Beasley, CM; Potvin, JH; Tamura, RN; Tollefson, GD; Tran, PV | 1 |
| Beasley, CM; Crawford, AM; Tollefson, GD | 1 |
| Beasley, CM; Genduso, LA; Hamilton, SH; Revicki, DA | 1 |
| Mattes, JA | 1 |
| Hillard, JR | 1 |
| Berman, A; Greaney, JJ; Madrid, A; Narendran, R; Pike, S; Tohen, M; Zarate, CA | 1 |
| Lu, Y; Sanger, TM; Thieme, ME; Tollefson, GD | 1 |
| Bymaster, FP; Li, XM; Perry, KW; Wong, DT | 1 |
| Allan, ER; Alpert, M; Connolly, B; Crichton, J; Sison, CE | 1 |
| Beasley, CM; Sanger, TM; Tollefson, GD; Tran, PV | 1 |
| Bartko, JJ; Conley, RR; Gounaris, C; Hegerty, J; Lingle, J; Love, R; Peszke, M; Richardson, C; Tamminga, CA; Zaremba, S | 1 |
| Dai, J; Ichikawa, J; Kuroki, T; Meltzer, HY | 1 |
| Bailey, RK; Dralle, PW; Eschmann, AJ; Strauss, AJ; Wagner, RB | 1 |
| Licht, RW | 1 |
| Almeida, OP | 1 |
| Koch, T; Korf, J; Sebens, JB; Ter Horst, GJ | 1 |
| Nemeroff, CB; Owens, MJ; Radke, JM; Ritchie, JC | 1 |
| Gao, XM; Sakai, K; Tamminga, CA | 1 |
| Beasley, CM; Dellva, MA; Tollefson, GD; Tran, PV; Wentley, AL | 1 |
| Depoortere, R; Perrault, G; Sanger, DJ | 1 |
| de Boer, P; de Vries, JB; Kruse, CG; Long, SK; Westerink, BH | 1 |
| Beasley, C; Grundy, S; Lieberman, JA; Sanger, TM; Tohen, M; Tollefson, GD | 1 |
| Arrang, JM; Morisset, S; Sahm, UG; Schwartz, JC; Tardivel-Lacombe, J; Traiffort, E | 1 |
| Asenbaum, S; Barnas, C; Brücke, T; Fischer, P; Kasper, S; Küfferle, B; Pezawas, L; Tauscher, J; Tauscher-Wisniewski, S | 1 |
| Abraham, D; Kissling, W; Leucht, S; Pitschel-Walz, G | 1 |
| Haack, M; Hinze-Selch, D; Kraus, T; Kühn, M; Pollmächer, T; Schuld, A; Uhr, M | 1 |
| De Bittencourt, PR; Hanel, RA; Kranich, M; Sandmann, MC | 1 |
| Breier, A; Hamilton, SH | 1 |
| Cooper, M; Passik, SD | 1 |
| Brown, RE; Genduso, LA; Hamilton, SH; Palmer, CS; Revicki, DA | 1 |
| Breier, A | 1 |
| Beasley, CM; Berg, PH; Lu, Y; Sanger, TM; Tollefson, GD; Tran, PV | 1 |
| Beasley, CM; Dellva, MA; Ferguson, K; Glazer, WM; Morgenstern, H; Tamura, RN; Tollefson, GD | 1 |
| Kapur, S; Remington, G | 2 |
| Gomberg, RF | 1 |
| Alsayegh, L; Backstrom, JR; Berry, SA; Friedman, L; Roth, BL; Sanders-Bush, E; Willins, DL | 1 |
| Crismon, ML; Dorson, PG; Lee, JW | 1 |
| Berisford, MA; Goldstein, D; Kysar, L; Marder, SR; Mintz, J; Pashdag, J; Wirshing, DA; Wirshing, WC | 1 |
| Carboni, E; Di Chiara, G; Rolando, MT; Silvagni, A | 1 |
| Croghan, TW; Heilman, DK; Johnstone, BM; Obenchain, RL; Tunis, SL | 1 |
| Bruggeman, R; den Boer, JA; Heijmen, M; Timmerman, W; Westerink, BH | 1 |
| Berk, M; Brook, S; Trandafir, AI | 1 |
| Beasley, CM; Ganoczy, D; Genduso, LA; Hamilton, SH; Revicki, DA | 1 |
| Beuzen, JN; Taylor, N; Wesnes, K; Wood, A | 1 |
| Yui, K | 1 |
| Dulisse, BK; Gibson, PJ; Johnstone, BM; Loosbrock, DL; Tunis, SL | 1 |
| Kaplan, GB; Keith, DJ; Leite-Morris, KA | 1 |
| Edgell, ET; Genduso, LA; Hamilton, SH; Revicki, DA; Tollefson, G | 1 |
| Annoh, N; Harano, M; Tanaka, M; Yamada, S | 1 |
| Fukuda, K; Hondo, H; Kuroki, T; Nakahara, T; Tsutsumi, T; Uchimura, H; Yao, H | 1 |
| Bedwell, J; Gochman, P; Hamburger, SD; Lenane, MC; Nicolson, R; Rapoport, JL; Spechler, L; Wudarsky, M | 1 |
| Heal, DJ; Kilpatrick, IC; Needham, PL; Rowley, HL | 1 |
| Addington, D; Breier, A; David, SR; Jones, BD; Labelle, A; Purdon, SE; Stip, E; Tollefson, GD | 1 |
| Hashimoto, K; Hirano, M; Hondo, H; Kuroki, T; Motomura, K; Nakahara, T; Tsutsumi, T; Uchimura, H; Ueki, H | 1 |
| Hawk, RM; Karson, CN; Komoroski, RA; Lindquist, DM | 1 |
| Glazer, WM | 1 |
| McCallum, SE; Porter, JH; Vann, RE; Varvel, SA | 1 |
| Devoto, P; Diana, M; Flore, G; Gessa, GL; Melis, M; Pistis, M | 1 |
| Woods, SW | 2 |
| Fujimura, M; Hashimoto, K; Yamagami, K | 1 |
| Gómez, JC; Gregor, KJ; Montejo, AL; Sacristán, JA; Vieta, E | 1 |
| Coutureau, E; Di Scala, G; Gosselin, O | 1 |
| Lu, Y; Rollema, H; Schmidt, AW; Sprouse, JS; Zorn, SH | 1 |
| Almond, S; O'Donnell, O | 1 |
| Breier, A; Edgell, ET; Hamilton, SH; Revicki, DA | 1 |
| Arvanov, V; Jardemark, KE; Liang, X; Wang, RY | 1 |
| Breier, A; David, SR; Kinon, BJ; Taylor, CC | 1 |
| Roberts, RC | 1 |
| Robinson, KA | 1 |
| Klein, HE; Müller, JL | 1 |
| Shulman, RW | 1 |
| Feifel, D | 1 |
| Gao, XM; Hashimoto, T; Sakai, K; Tamminga, CA | 1 |
| Damodaran, SS; Thankamma, JK | 1 |
| Hägg, S; Lindqvist, L; Mjörndal, T | 1 |
| Marsh, C; Preskorn, SH; Shad, MU | 1 |
| Hilger, E; Kasper, S | 1 |
| Bhana, N; Foster, RH; Olney, R; Plosker, GL | 1 |
| Kapur, S; Seeman, P | 1 |
| Hill, AL; Kinon, BJ; Milton, DR; Roychowdhury, SM | 1 |
| Jones, B; Meehan, K; Taylor, CC | 1 |
| Basson, BR; Crawford, AM; Jones, B; Kinon, BJ; Walker, DJ | 1 |
| Crawford, AM; Gomez, JC | 1 |
| Basson, BR; Gilmore, JA; Kinon, BJ; Tollefson, GD | 1 |
| Mujica, R; Weiden, P | 1 |
| Gundlapalli, SP; Iqbal, MM; Passman, TE; Ryals, T; Ryan, WG | 1 |
| Beasley, CM; Berg, PH; Czekalla, J; Dellva, MA; Grundy, S | 1 |
| Hatzimanolis, J; Lykouras, L; Markianos, M; Oulis, P | 1 |
| Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD | 1 |
| Agarwal, V; Kumar, P | 1 |
| Basturk, M; Esel, E; Kula, M; Saffet Gonul, A; Sofuoglu, S; Tayfun Turan, M; Yabanoglu, I | 1 |
| Alaka, KJ; Bernardo, M; Birkett, M; Bradley, P; Breier, A; David, SR; Ferchland, I; Krueger, J; Meehan, K; Reinstein, M; San, L; Saunders, JC; Wright, P | 1 |
| Deslandes, M; Edwardes, MD; Laporta, M; Ricard, N; Sauriol, L; Suissa, S | 1 |
| Inada, T; Ishigooka, J; Miura, S | 1 |
| Alvarez, N; Costa e Silva, JA; Cousins, L; Gattaz, WF; Larach, V; Mazzotti, G; Oliva, D; Ospina, J; Starkstein, S; Taylor, CC; Tohen, M; Tran, PV; Wang, J | 1 |
| Cater, J; Choudhury, MS; Delaney, MA; Malone, RP; Sheikh, RM | 1 |
| Howard, HR; Lebel, LA; Schmidt, AW; Zorn, SH | 1 |
| Reuss, B; Unsicker, K | 1 |
| Copolov, DL; Dean, B; Hussain, T; Pavey, G; Scarr, E | 1 |
| Bernardo, M; Catafau, AM; Font, M; Gómez, JC; Gutiérrez, F; Lomeña, F; López-Carrero, C; Parellada, E; Pavía, J; Salamero, M | 1 |
| Andersen, MP; Pouzet, B | 1 |
| Atkins, A; Cilia, J; Foxton, R; Hagan, JJ; Heidbreder, CA; Hughes, ZA; Hunter, AJ; Jones, DN; Shah, AJ | 1 |
| Infante, M; Khandat, A; Singh, A; Smith, RC | 1 |
| Badía, X; Gómez, JC; Kind, P; Sacristán, JA | 1 |
| Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J | 1 |
| Hatzimanolis, J; Lykouras, L; Markianos, M | 1 |
| Bauzon, D; Bymaster, FP; Cohen, ML; DeLapp, NW; Falcone, JF; Kennedy, JS; Schenck, K | 1 |
| Cohen, H; Kotler, M; Loewenthal, U; Matar, M | 1 |
| de Boer, A; Herings, RM; Jansen, PA; Leufkens, HG; Roos, RA; Schillevoort, I | 1 |
| Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J | 2 |
| Aloj, L; Ambesi-Impiombato, A; Barone, P; Bravi, D; Caracò, C; de Bartolomeis, A; Muscettola, G | 1 |
| Dai, J; Fowler, WL; Ichikawa, J; Meltzer, HY; O'Laughlin, IA | 1 |
| Breier, A; Feldman, PD; Keck, PE; Risser, RC; Tohen, M; Tran, PV; Zhang, F | 1 |
| Philibin, SD; Porter, JH; Vann, RE; Varvel, SA; Wise, LE | 1 |
| Apter, A; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Phillip, M; Ratzoni, G; Reidman, J; Weizman, R | 1 |
| Berg, PH; Glick, ID | 1 |
| Yatham, LN | 1 |
| Nomikos, GG; Rodriguez, DE; Shirazi-Southall, S | 1 |
| Klein, HE; Müller, JL; Röder, C; Schuierer, G | 1 |
| Birkett, M; Breier, A; Brook, S; David, S; Dossenbach, M; Ferchland, I; Kiesler, G; Meehan, K; Palmer, R; Sutton, V; Taylor, CC; Wright, P | 1 |
| Klein, H; Müller, JL; Röder, CH; Schuierer, G | 1 |
| Andersen, S; Cohen, LS; Crawford, A; Goldstein, JM; Horton, NJ; Lee, H; Tohen, M; Tollefson, G | 1 |
| Breese, GR; Moy, SS | 1 |
| Bilder, RM; Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Goldman, RS; Hoptman, M; Horowitz, TL; Kunz, M; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J | 1 |
| Apter, A; Constantini, N; Falk, B; Frishman, S; Gothelf, D; Kairi, M; Phillip, M; Poraz, I; Singer, P; Weizman, A; Zalsman, G; Zigel, L | 1 |
| Le Pen, G; Moreau, JL | 1 |
| Christodoulou, GN; Hatzimanolis, J; Lykouras, L; Markianos, M | 1 |
| Chiu, FC; Mahadik, SP; Wakade, CG; Waller, JL | 1 |
| Quartermain, D; Rosengarten, H | 1 |
| Breier, A; Edgell, ET; Gandhi, G; Haro, JM; Namjoshi, MA; Shi, L; Tohen, M; Zhang, F | 1 |
| Alfaro, CL; Gochman, P; Lenane, M; Nicolson, R; Rapoport, JL; Sporn, A; Wudarsky, M | 1 |
| Alkhouri, I; Champine, D; Fluent, T; Ghaziuddin, M; Ghaziuddin, N; Quinlan, P | 1 |
| Inada, T; Miura, S; Yagi, G | 1 |
| König, F; Raape, J; Truöl, S; Von Hippel, C | 1 |
| Dean, B; Parkin, FM; Pavey, G; Scarr, E | 1 |
| Douyon, K; Franco, K; Hadi, F; Hermida, T | 1 |
| Ballon, JS; Boyd, JA; Marder, SR; Meng, LR; Wirshing, DA; Wirshing, WC | 1 |
| Bilici, M; Cakirbay, H; Guler, M; Tan, U; Tosun, M; Ulgen, M | 1 |
| de Haan, L; van Amelsvoort, T | 1 |
| Barak, Y; Mirecki, I; Shamir, E; Toren, P; Weizman, R; Zemishlani, H | 1 |
| Hägg, S; Hedenmalm, K; Mortimer, O; Spigset, O; Ståhl, M | 1 |
| Evans, DR; Hill, WD; Mahadik, SP; Parikh, V; Terry, AV; Waller, JL | 1 |
| Bai, O; Bowen, R; Chlan-Fourney, J; Keegan, D; Li, XM | 1 |
| Alvarez, E; Bobes, J; Cañas, F; Carrasco, JL; Gascón, J; Gibert, J; Gómez, JC; Gutiérrez, M; Sacristán, JA | 1 |
| Beasley, CM; Inada, T; Tanaka, Y; Walker, DJ | 1 |
| Duncan, GE; Lieberman, JA; Marx, CE; Morrow, AL; VanDoren, MJ | 1 |
| Daniel, DG | 1 |
| Aguglia, E; De Vanna, M; Ferrara, D; Onor, ML | 1 |
| Atmaca, M; Gecici, O; Kuloglu, M; Tezcan, E; Ustundag, B | 1 |
| Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D; van Bruggen, M | 1 |
| Kalkman, HO; Loetscher, E | 1 |
| Meibach, RC | 1 |
| Messori, A | 1 |
| Gupta, S | 2 |
| Duncan, GE; Lieberman, JA; Miyamoto, S | 1 |
| Jardemark, KE; Ninan, I; Wang, RY | 1 |
| Gilmore, JA; Halbreich, UM; Kinon, BJ; Liu, H | 1 |
| Clifton, PG; Hartfield, AW; Moore, NA | 1 |
| Fischer-Barnicol, D; Koch, HJ; Szecsey, A; Vogel, M | 1 |
| Brown, CM; Gibson, PJ; Opolka, JL; Rascati, KL | 1 |
| Cherkerzian, S; Cohen, BM; Lange, N; Ma, J; Wager, C; Ye, N | 1 |
| Leander, JD; Wolff, MC | 1 |
| Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R | 1 |
| Bedogni, F; Fossati, C; Fumagalli, F; Gennarelli, M; Molteni, R; Racagni, G; Riva, MA; Roceri, M; Santero, R | 1 |
| Kreilgaard, M; Mow, T; Pouzet, B; Velschow, S | 1 |
| Bobes, J; Fernández, I; Garcia-Garcia, M; García-Portilla, MP; Hernández, G; Rejas, J; Rico-Villademoros, F | 1 |
| Gaisler-Salomon, I; Green, A; Joel, D; Schiller, D; Weiner, I | 1 |
| Harvey, BH; Nel, A | 1 |
| Alaka, K; Battaglia, J; Lindborg, SR; Meehan, K; Wright, P | 1 |
| Barner, JC; Brown, CM; Gibson, PJ; Johnsrud, MT; Opolka, JL; Rascati, KL | 1 |
| Lindborg, SR; Purdon, SE; Stip, E; Woodward, N | 1 |
| Grottick, AJ; Herberg, LJ; Montgomery, AM | 1 |
| Conley, RR; Kelly, DL; Love, RC; McMahon, RP | 1 |
| Coutureau, E; Di Scala, G; Herbeaux, K; Majchrzak, M; Seillier, A; Thiriet, N; Will, B; Zwiller, J | 1 |
| Birkett, M; Breier, A; Lindborg, SR; Meehan, K; Morris, P; Taylor, CC; Wright, P | 1 |
| Becker, T; Kopf, A; Köster, J; Krömker, H; Schulz, A | 1 |
| Green, AI; Gur, RE; Hamer, RM; Kahn, R; Lieberman, JA; McEvoy, J; Perkins, D; Sharma, T; Tohen, M; Tollefson, G; Wei, H; Zipursky, R | 1 |
| Khan, MM; Mahadik, SP; Parikh, VV | 1 |
| Lin, DA; Zareba, W | 1 |
| Christensen, BK; Daskalakis, ZJ; Kapur, S; Kiang, M; Remington, G | 1 |
| Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H | 1 |
| Brunnauer, A; Geiger, E; Laux, G | 1 |
| Gibson, CJ; Hamm, RJ; Wilson, MS | 1 |
| Bashford, RA; Hamer, RM; Lieberman, JA; Sheitman, BB; Sikich, L | 1 |
| Arango, C; Buchanan, RW; Summerfelt, A | 1 |
| Breier, A; Bymaster, FP; Dossenbach, M; Gilmore, JA; Golshan, S; Jeste, D; Kaiser, CJ; Kennedy, JS; Kinon, BJ; Maguire, GA; Sanger, T; Tollefson, G | 1 |
| Amano, N; Ushizima, M | 1 |
| Hasui, Y; Ikeda, M; Tanabe, H | 1 |
| Deuticke, C; Hajak, G; Müller, JL; Putzhammer, A; Röder, CH; Winkler, J | 1 |
| Cetin, I; Guner, P; Soygur, H; Sungur, MZ; Ustun, B | 1 |
| Allan, E; Bingham, S; Campbell, EC; Caroff, S; Collins, J; Corwin, J; Davis, L; Douyon, R; Dunn, L; Evans, D; Frecska, E; Grabowski, J; Graeber, D; Herz, L; Kwon, K; Lawson, W; Leslie, D; Liu-Mares, W; Mena, F; Perlick, D; Rosenheck, R; Sheikh, J; Smelson, D; Smith-Gamble, V; Warren, S | 1 |
| Azorin, JM; Baker, RW; Breier, A; Emsley, RA; Evans, AR; Goldberg, JF; Gonzalez-Pinto Arrillaga, AM; Hardy-Bayle, MC; Lawson, WB; Namjoshi, MA; Risser, RC; Tohen, M; Vieta, E; Zhang, F | 1 |
| Tamminga, CA | 1 |
| Han, M; Huang, XF; Nguyen, VH; Zavitsanou, K | 1 |
| Gozes, I; Malkoff, A; Rehavi, M; Weizman, A | 1 |
| Alvarez-Cervera, FJ; Bata-García, JL; Erosa-Rivero, HB; Góngora-Alfaro, JL; Heredia-López, FJ | 1 |
29 review(s) available for haloperidol and pirenzepine
| Article | Year |
|---|---|
Efficacy of olanzapine: an overview of pivotal clinical trials.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Haloperidol; Humans; Male; Multicenter Studies as Topic; Olanzapine; Pirenzepine; Placebos; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1997 |
Safety of olanzapine.
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Clinical Trials as Topic; Cross-Over Studies; Dizziness; Double-Blind Method; Dystonia; Haloperidol; Heart Rate; Humans; Liver; Olanzapine; Parkinson Disease, Secondary; Pirenzepine; Placebos; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Sleep; Transaminases; Treatment Outcome; Weight Gain | 1997 |
Dosing the antipsychotic medication olanzapine.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Prolactin; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology | 1997 |
Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Cost-Benefit Analysis; Data Collection; Double-Blind Method; Drug Costs; Economics, Pharmaceutical; Haloperidol; Health Care Costs; Humans; Olanzapine; Patient Selection; Pirenzepine; Research Design; Schizophrenia; Treatment Outcome | 1997 |
The relationship of pharmacology to side effects.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Parkinson Disease, Secondary; Pirenzepine; Receptors, Neurotransmitter; Seizures; Sleep; Weight Gain | 1997 |
Emergency treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Decision Trees; Drug Administration Schedule; Emergency Services, Psychiatric; Emergency Treatment; Haloperidol; History, 20th Century; Humans; Lorazepam; Olanzapine; Pirenzepine; Psychotic Disorders; Risperidone | 1998 |
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dibenzothiazepines; Double-Blind Method; Haloperidol; Humans; Imidazoles; Indoles; Olanzapine; Pirenzepine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 1999 |
Cognitive deficit in schizophrenia and its neurochemical basis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Glutamic Acid; Haloperidol; Humans; N-Methylaspartate; Olanzapine; Pirenzepine; Risperidone; Schizophrenia; Schizophrenic Psychology | 1999 |
D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET.
Topics: Amoxapine; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Dopamine Antagonists; Haloperidol; Humans; In Vitro Techniques; Loxapine; Olanzapine; Pirenzepine; Quetiapine Fumarate; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Serotonin Antagonists; Tomography, Emission-Computed | 1999 |
[Clinical efficacy of olanzapine].
Topics: Antipsychotic Agents; Benzodiazepines; Binding Sites; Clinical Trials as Topic; Clozapine; Dopamine D2 Receptor Antagonists; Haloperidol; Humans; Olanzapine; Pirenzepine; Risperidone; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Serotonin | 1999 |
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Haloperidol; Humans; Incidence; Molindone; Olanzapine; Pirenzepine; Prospective Studies; Risk Factors; Risperidone; Schizophrenia; Substance Withdrawal Syndrome; Survival Analysis | 2000 |
The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Dose-Response Relationship, Drug; Haloperidol; Humans; Olanzapine; Pirenzepine; Prolactin; Risperidone; Schizophrenia | 2000 |
Rationale and guidelines for the inpatient treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Schedule; Drug Therapy, Combination; Haloperidol; Hospitalization; Hostility; Humans; Olanzapine; Pirenzepine; Practice Guidelines as Topic; Psychomotor Agitation; Psychotic Disorders; Risperidone; Treatment Outcome | 2000 |
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; Dopamine Antagonists; Drug Monitoring; Haloperidol; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Receptors, Dopamine D2; Receptors, Dopamine D4; Risperidone; Schizophrenia; Schizophrenic Psychology; Serotonin Antagonists; Sulpiride; Thiazoles; Treatment Outcome | 2001 |
[Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders].
Topics: Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dibenzothiazepines; Dibenzothiepins; Haloperidol; Humans; Imidazoles; Indoles; Multicenter Studies as Topic; Olanzapine; Piperazines; Pirenzepine; Placebos; Quetiapine Fumarate; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sulpiride; Thiazoles | 2000 |
Olanzapine: an updated review of its use in the management of schizophrenia.
Topics: Adolescent; Aged; Animals; Antipsychotic Agents; Benzodiazepines; Child; Child, Preschool; Cognition Disorders; Cost-Benefit Analysis; Cytochrome P-450 Enzyme System; Depression; Drug Interactions; Haloperidol; Humans; Olanzapine; Pirenzepine; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Serotonin; Risperidone; Schizophrenia | 2001 |
Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
Topics: Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Dopamine D2 Receptor Antagonists; Haloperidol; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Receptors, Dopamine D2; Receptors, Dopamine D4; Receptors, Serotonin; Risperidone; Schizophrenia; Terminology as Topic; Tomography, Emission-Computed | 2001 |
Weight change and atypical antipsychotic treatment in patients with schizophrenia.
Topics: Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Dose-Response Relationship, Drug; Follow-Up Studies; Haloperidol; Health Behavior; Humans; Obesity; Olanzapine; Pirenzepine; Risperidone; Schizophrenia; Weight Gain | 2001 |
Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Antimanic Agents; Benzodiazepines; Breast Feeding; Carbamazepine; Cyclohexanecarboxylic Acids; Female; Fetus; Gabapentin; gamma-Aminobutyric Acid; Haloperidol; Humans; Infant, Newborn; Lithium; Mood Disorders; Olanzapine; Pirenzepine; Placenta; Pregnancy; Risk Factors; Valproic Acid | 2001 |
Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Drug Therapy, Combination; Haloperidol; Humans; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Treatment Outcome | 2001 |
The role of novel antipsychotics in bipolar disorders.
Topics: Acute Disease; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Haloperidol; Humans; Lithium; Olanzapine; Pirenzepine; Randomized Controlled Trials as Topic; Risperidone | 2002 |
Recent developments in pharmacotherapy for the acutely psychotic patient.
Topics: Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Injections, Intramuscular; Olanzapine; Piperazines; Pirenzepine; Psychomotor Agitation; Psychotic Disorders; Thiazoles | 2002 |
Safety in treating bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Dyskinesias; Haloperidol; Humans; Hyperglycemia; Hyperprolactinemia; Olanzapine; Pirenzepine; Quetiapine Fumarate; Risperidone; Thioridazine; Weight Gain | 2003 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Therapeutic Equivalency; Thiazoles | 2003 |
[Life threatening neuroleptic malignant syndrome due to olanzapine].
Topics: Antipsychotic Agents; Benzodiazepines; Critical Care; Electroconvulsive Therapy; Female; Haloperidol; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Olanzapine; Pirenzepine; Psychotic Disorders; Recurrence | 2003 |
Antipsychotic drugs and QT interval prolongation.
Topics: Age Factors; Algorithms; Antipsychotic Agents; Benzodiazepines; Death, Sudden, Cardiac; Dopamine Antagonists; Drug Labeling; Haloperidol; Humans; Long QT Syndrome; Olanzapine; Pirenzepine; Sex Factors; Thioridazine; Torsades de Pointes | 2003 |
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cholinergic Antagonists; Clozapine; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Placebos; Randomized Controlled Trials as Topic; Retrospective Studies; Risperidone; Schizophrenia | 2003 |
[Brain tumor].
Topics: Antipsychotic Agents; Benzodiazepines; Brain Neoplasms; Haloperidol; Humans; Hydrocephalus; Immunoglobulins, Intravenous; Intracranial Hypertension; Mental Disorders; Olanzapine; Pirenzepine; Seizures | 2003 |
[Porphyria].
Topics: 5-Aminolevulinate Synthetase; Analgesics, Opioid; Antipsychotic Agents; Arginine; Benzodiazepines; Ferrochelatase; Haloperidol; Heme; Humans; Hydroxymethylbilane Synthase; Olanzapine; Pirenzepine; Plasma Exchange; Porphyria, Acute Intermittent; Prognosis | 2003 |
74 trial(s) available for haloperidol and pirenzepine
| Article | Year |
|---|---|
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Schizophrenia | 1996 |
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive Disorder; Double-Blind Method; Europe; Female; Haloperidol; Humans; Male; North America; Olanzapine; Patient Dropouts; Pirenzepine; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1997 |
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Haloperidol; Hospitalization; Humans; Male; Middle Aged; Models, Statistical; Neurotransmitter Agents; Olanzapine; Pirenzepine; Placebos; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1997 |
Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Schizophrenia | 1997 |
Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Drug Administration Schedule; Drug Tolerance; Female; Haloperidol; Humans; Incidence; Male; Olanzapine; Patient Compliance; Patient Dropouts; Pirenzepine; Schizophrenia; Treatment Outcome | 1997 |
Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Cost-Benefit Analysis; Data Collection; Double-Blind Method; Drug Costs; Economics, Pharmaceutical; Haloperidol; Health Care Costs; Humans; Olanzapine; Patient Selection; Pirenzepine; Research Design; Schizophrenia; Treatment Outcome | 1997 |
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Incidence; Male; Olanzapine; Pirenzepine; Placebos; Psychotic Disorders; Schizophrenia; Severity of Illness Index; Treatment Outcome | 1997 |
The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Cross-Sectional Studies; Dopamine Antagonists; Double-Blind Method; Female; Haloperidol; Humans; Hyperprolactinemia; Longitudinal Studies; Male; Olanzapine; Pirenzepine; Schizophrenia; Sex Distribution; Time Factors | 1997 |
Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Quality of Life; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1998 |
Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Depressive Disorder; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Prospective Studies; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Treatment Outcome | 1998 |
The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 1998 |
A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.
Topics: Adult; Antipsychotic Agents; Anxiety; Benzodiazepines; Depression; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 1998 |
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Rating Scale; Chlorpromazine; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Headache; Humans; Male; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Sleep Stages; Treatment Outcome; Xerostomia | 1998 |
Olanzapine versus haloperidol treatment in first-episode psychosis.
Topics: Age of Onset; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Rating Scale; Double-Blind Method; Haloperidol; Humans; Olanzapine; Pirenzepine; Prospective Studies; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Time Factors; Treatment Outcome | 1999 |
In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzamides; Benzodiazepines; Clozapine; Contrast Media; Corpus Striatum; Female; Haloperidol; Humans; Iodine Radioisotopes; Male; Middle Aged; Olanzapine; Pirenzepine; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 1999 |
Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Behavioral Symptoms; Benzodiazepines; Chi-Square Distribution; Double-Blind Method; Drug Resistance; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Prospective Studies; Schizophrenia; Treatment Outcome | 1999 |
Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?
Topics: Antipsychotic Agents; Anxiety; Benzodiazepines; Brief Psychiatric Rating Scale; Depression; Double-Blind Method; Haloperidol; Humans; Olanzapine; Pirenzepine; Schizophrenia; Schizophrenic Psychology | 1999 |
Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Prospective Studies; Psychotic Disorders; Treatment Outcome | 1999 |
Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
Topics: Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Pirenzepine; Risk Factors; Schizophrenia; Survival Analysis | 1999 |
Novel antipsychotics: comparison of weight gain liabilities.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; Imidazoles; Indoles; Male; Obesity; Olanzapine; Pirenzepine; Placebos; Retrospective Studies; Risperidone; Schizophrenia; Weight Gain | 1999 |
Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol.
Topics: Activities of Daily Living; Adult; Antipsychotic Agents; Benzodiazepines; Cost of Illness; Cost-Benefit Analysis; Discriminant Analysis; Factor Analysis, Statistical; Female; Haloperidol; Health Status Indicators; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Psychometrics; Reproducibility of Results; Schizophrenia; Surveys and Questionnaires; Treatment Outcome | 1999 |
A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cannabis; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Psychoses, Substance-Induced | 1999 |
Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Europe; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Quality of Life; Schizophrenia | 1999 |
A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers.
Topics: Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Attention; Benzodiazepines; Cognition; Cross-Over Studies; Double-Blind Method; Female; Haloperidol; Humans; Male; Mental Recall; Middle Aged; Neuropsychological Tests; Olanzapine; Pirenzepine; Psychomotor Performance; Reaction Time | 1999 |
Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Female; Haloperidol; Health Care Costs; Health Status; Hospitalization; Humans; Male; Olanzapine; Personality Inventory; Pirenzepine; Psychiatric Status Rating Scales; Schizophrenia | 1999 |
Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Haloperidol; Humans; Olanzapine; Pirenzepine; Schizophrenia; Treatment Outcome; United States | 1999 |
The impact of schizophrenic patient functionality on service utilization and cost. Based on a presentation by Sandra L. Tunis, PhD.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Haloperidol; Hospital Costs; Humans; Olanzapine; Pirenzepine; Quality of Life; Schizophrenia; Treatment Outcome; United States | 1999 |
Elevated prolactin in pediatric patients on typical and atypical antipsychotics.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Child; Clozapine; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Prolactin; Sex Factors | 1999 |
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Motor Skills; Neuropsychological Tests; Olanzapine; Pirenzepine; Psychomotor Performance; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2000 |
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Haloperidol; Humans; Incidence; Molindone; Olanzapine; Pirenzepine; Prospective Studies; Risk Factors; Risperidone; Schizophrenia; Substance Withdrawal Syndrome; Survival Analysis | 2000 |
Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample.
Topics: Activities of Daily Living; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Hospitalization; Humans; Male; Middle Aged; Occupations; Olanzapine; Pirenzepine; Schizophrenia; Social Behavior; Treatment Outcome | 2000 |
Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Prospective Studies; Psychiatric Status Rating Scales; Psychomotor Agitation; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2001 |
The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Hospitalization; Humans; Injections, Intramuscular; Male; Olanzapine; Pirenzepine; Psychomotor Agitation; Schizophrenia; Schizophrenic Psychology; Single-Blind Method; Treatment Outcome | 2001 |
Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Female; Haloperidol; Hospitalization; Humans; Male; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2001 |
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Cholesterol; Diastole; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Longitudinal Studies; Male; Olanzapine; Pirenzepine; Psychotic Disorders; Retrospective Studies; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Weight Gain | 2001 |
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.
Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agents; Arrhythmias, Cardiac; Benzodiazepines; Electrocardiography; Female; Haloperidol; Humans; Incidence; Long QT Syndrome; Male; Middle Aged; Olanzapine; Pirenzepine; Placebos; Risperidone; Schizophrenia | 2001 |
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
Topics: Adult; Age Factors; Antipsychotic Agents; Appetite; Benzodiazepines; Body Mass Index; Body Weight; Brief Psychiatric Rating Scale; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Racial Groups; Retrospective Studies; Risk Factors; Risperidone; Schizophrenia; Sex Factors; Treatment Outcome; Weight Gain | 2001 |
Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Prolactin; Schizophrenia | 2001 |
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Olanzapine; Pirenzepine; Placebos; Psychiatric Status Rating Scales; Psychomotor Agitation; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2001 |
Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Patient Compliance; Pirenzepine; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2001 |
Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Latin America; Male; Middle Aged; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome | 2001 |
Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.
Topics: Antipsychotic Agents; Autistic Disorder; Benzodiazepines; Child; Child Development Disorders, Pervasive; Child, Preschool; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Olanzapine; Pilot Projects; Pirenzepine; Treatment Outcome | 2001 |
Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzamides; Benzodiazepines; Contrast Media; Corpus Striatum; Double-Blind Method; Female; Frontal Lobe; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Prospective Studies; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 2001 |
The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cognition; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Memory; Middle Aged; Neuropsychological Tests; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 2001 |
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Blind Method; Emotions; Female; Haloperidol; Hostility; Humans; Linear Models; Male; Olanzapine; Pirenzepine; Prospective Studies; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Statistics, Nonparametric; Survival Analysis | 2001 |
Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dopamine Antagonists; Dose-Response Relationship, Drug; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Pituitary Gland; Prolactin; Receptors, Dopamine D2; Risperidone; Schizophrenia; Sulpiride | 2001 |
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Patient Admission; Pirenzepine; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2002 |
Olanzapine versus haloperidol in schizoaffective disorder, bipolar type.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Psychotic Disorders; Severity of Illness Index; Treatment Outcome | 2001 |
Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Recurrence; Risperidone; Schizophrenia; Substance Withdrawal Syndrome; Survival Analysis; Time Factors; Treatment Outcome; Treatment Refusal | 2002 |
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Olanzapine; Pirenzepine; Placebos; Psychiatric Status Rating Scales; Psychomotor Agitation; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2002 |
Sex differences in clinical response to olanzapine compared with haloperidol.
Topics: Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Schizophrenia; Schizophrenic Psychology; Sex Factors; Treatment Outcome | 2002 |
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Double-Blind Method; Female; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Pirenzepine; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2002 |
Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Eating; Energy Intake; Energy Metabolism; Haloperidol; Hospitalization; Humans; Male; Obesity; Olanzapine; Physical Exertion; Pilot Projects; Pirenzepine; Schizophrenia; Weight Gain | 2002 |
Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Quality of Life; Treatment Outcome; Work | 2002 |
Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Incidence; Japan; Male; Middle Aged; Olanzapine; Pirenzepine; Schizophrenia; Statistics, Nonparametric | 2002 |
Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Bone Density; Clopenthixol; Clozapine; Female; Fluphenazine; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Risperidone; Schizophrenia | 2002 |
Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Retrospective Studies; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2002 |
Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Prospective Studies; Psychiatric Status Rating Scales; Safety; Schizophrenia; Treatment Outcome | 2003 |
Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Diagnosis, Differential; Female; Haloperidol; Humans; Incidence; Male; Middle Aged; Odds Ratio; Olanzapine; Pirenzepine; Prevalence; Psychiatric Status Rating Scales; Retrospective Studies; Schizophrenia | 2003 |
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Clozapine; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Hospitalization; Humans; Hypercholesterolemia; Hyperglycemia; Male; Middle Aged; Olanzapine; Pirenzepine; Prospective Studies; Psychotic Disorders; Risperidone; Schizophrenia; Weight Gain | 2003 |
Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Corpus Striatum; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Haloperidol; Humans; Iodobenzenes; Male; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2003 |
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Depression; Dopamine Antagonists; Dyskinesia, Drug-Induced; Fatigue; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Treatment Outcome | 2003 |
Calming versus sedative effects of intramuscular olanzapine in agitated patients.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dementia; Double-Blind Method; Drug Administration Schedule; Haloperidol; Humans; Hypnotics and Sedatives; Injections, Intramuscular; Lorazepam; Olanzapine; Pirenzepine; Psychomotor Agitation; Retrospective Studies; Schizophrenia; Treatment Outcome | 2003 |
Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Double-Blind Method; Female; Haloperidol; Humans; Learning; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Outpatients; Pirenzepine; Risperidone; Schizophrenia; Time Factors | 2003 |
A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Olanzapine; Pirenzepine; Schizophrenia | 2003 |
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2003 |
Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Haloperidol; Humans; Middle Aged; Motor Activity; Muscle Rigidity; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales | 2003 |
A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Olanzapine; Pilot Projects; Pirenzepine; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Time Factors; Treatment Outcome | 2004 |
Olanzapine effects on auditory sensory gating in schizophrenia.
Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Auditory Perception; Benzodiazepines; Evoked Potentials, Auditory; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Reflex, Startle; Schizophrenia | 2003 |
Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Dose-Response Relationship, Drug; Double-Blind Method; Haloperidol; Humans; Middle Aged; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome | 2003 |
Schizophrenia and Parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: an fMRI fingertapping study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Dopamine; Female; Fingers; Functional Laterality; Haloperidol; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Movement; Olanzapine; Parkinson Disease; Pirenzepine; Psychiatric Status Rating Scales; Psychomotor Performance; Putamen; Schizophrenia; Schizophrenic Psychology; Thalamus | 2003 |
Optimal treatment project for schizophrenia: results from a randomized, controlled, longitudinal study.
Topics: Adaptation, Psychological; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Case Management; Cognitive Behavioral Therapy; Community Mental Health Services; Female; Haloperidol; Humans; Longitudinal Studies; Male; Middle Aged; Olanzapine; Patient Care Team; Pirenzepine; Quality Assurance, Health Care; Schizophrenia | 2003 |
Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Benztropine; Double-Blind Method; Female; Haloperidol; Health Care Costs; Health Services; Humans; Male; Middle Aged; Muscarinic Antagonists; Neuropsychological Tests; Olanzapine; Pirenzepine; Quality of Life; Schizophrenia; Treatment Outcome; United States | 2003 |
A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Personality Inventory; Pirenzepine; Psychiatric Status Rating Scales; Treatment Outcome | 2003 |
136 other study(ies) available for haloperidol and pirenzepine
| Article | Year |
|---|---|
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzofurans; Carrageenan; Disease Models, Animal; Drug Design; Drug Evaluation, Preclinical; Humans; Hyperalgesia; Ligands; Mice; Molecular Structure; Pain; Peritonitis; Quinazolines; Rats; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H4; Stereoisomerism; Structure-Activity Relationship | 2008 |
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
Topics: Analgesics; Animals; Benzimidazoles; Drug Design; Drug Evaluation, Preclinical; Humans; Microsomes, Liver; Neuralgia; Nociceptin Receptor; Pyrroles; Rats; Receptors, Opioid; Structure-Activity Relationship | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
Topics: Animals; Area Under Curve; Humans; Intestinal Absorption; Ligands; Male; Metabolic Clearance Rate; Models, Chemical; Models, Molecular; Molecular Structure; Protein Binding; Protein Structure, Tertiary; Pyrrolidinones; Radioligand Assay; Receptor, Serotonin, 5-HT1A; Receptors, Serotonin, 5-HT3; Serotonin 5-HT1 Receptor Agonists; Structure-Activity Relationship | 2013 |
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
Topics: Acetamides; Allosteric Regulation; Animals; Rats; Rats, Wistar; Receptors, sigma; Sigma-1 Receptor; Stereoisomerism; Structure-Activity Relationship | 2013 |
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Avoidance Learning; Benzoxazoles; Catalepsy; CHO Cells; Cricetulus; Dementia; Dopamine D2 Receptor Antagonists; HEK293 Cells; Humans; Male; Models, Molecular; Motor Activity; Radioligand Assay; Rats, Wistar; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship; Sulfonamides | 2014 |
Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Benzamides; Dementia; Dose-Response Relationship, Drug; Drug Partial Agonism; Humans; Indoles; Ligands; Male; Models, Molecular; Molecular Structure; Piperazines; Quinolones; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Serotonin; Structure-Activity Relationship; Swimming | 2015 |
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Topics: Amino Alcohols; Animals; Anticonvulsants; Chemistry, Physical; Dose-Response Relationship, Drug; Drug Design; Epilepsy; Male; Mice; Microsomes, Liver; Molecular Structure; Pilocarpine | 2016 |
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Topics: Amino Alcohols; Animals; Anticonvulsants; Crystallography, X-Ray; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Mice; Models, Molecular; Molecular Structure; Rats; Seizures; Structure-Activity Relationship | 2017 |
Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
Topics: Affect; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Dementia; Dopamine Agonists; Drug Design; Humans; Indoles; Ligands; Models, Molecular; Pyridines; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists | 2017 |
Pharmacologic characterization and functional role of muscarinic autoreceptors in the rabbit striatum.
Topics: Acetylcholine; Animals; Atropine; Carbachol; Corpus Striatum; Dose-Response Relationship, Drug; Drug Synergism; Haloperidol; Oxotremorine; Physostigmine; Pirenzepine; Quinuclidinyl Benzilate; Rabbits; Receptors, Muscarinic; Scopolamine; Time Factors | 1987 |
Olanzapine, an atypical antipsychotic, increases rates of punished responding in pigeons.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Chlordiazepoxide; Clozapine; Columbidae; Conditioning, Operant; Dose-Response Relationship, Drug; Haloperidol; Isoxazoles; Male; Olanzapine; Piperidines; Pirenzepine; Punishment; Risperidone | 1995 |
[Inhibitory effect of haloperidol on evoked dopamine release from striatal slices of the rat].
Topics: Acetylcholine; Animals; Carbachol; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; In Vitro Techniques; Pirenzepine; Rats; Rats, Wistar; Stimulation, Chemical | 1995 |
Effects of several amnesic drugs on the habituation of exploratory activity in mice as indexed by horizontal and vertical activities.
Topics: Amnesia; Animals; Behavior, Animal; Butylscopolammonium Bromide; Cycloheximide; Diazepam; Dizocilpine Maleate; Exploratory Behavior; Habituation, Psychophysiologic; Haloperidol; Male; Memory; Mice; Mice, Inbred Strains; Pirenzepine; Scopolamine | 1994 |
Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.
Topics: Adult; Antipsychotic Agents; Benzamides; Benzodiazepines; Corpus Striatum; Haloperidol; Humans; Middle Aged; Olanzapine; Pirenzepine; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1996 |
Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice.
Topics: Animals; Benzodiazepines; Clozapine; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Haloperidol; Male; Mice; Motor Activity; Olanzapine; Phencyclidine; Pirenzepine; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Receptors, Serotonin, 5-HT3; Serotonin Antagonists | 1997 |
BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; CHO Cells; Clozapine; Corpus Striatum; COS Cells; Cricetinae; Dibenzothiazepines; Dopamine; Female; Guinea Pigs; Haloperidol; Indoles; Kidney; Male; Microdialysis; Neuroblastoma; Nucleus Accumbens; Olanzapine; Piperazines; Pirenzepine; Prefrontal Cortex; Pyridines; Quetiapine Fumarate; Radioligand Assay; Rats; Rats, Sprague-Dawley; Risperidone; Tritium; Tumor Cells, Cultured | 1997 |
Olanzapine on trial.
Topics: Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Haloperidol; Humans; Olanzapine; Pirenzepine; Research Design; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1998 |
Clinical predictors of acute response with olanzapine in psychotic mood disorders.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Age Factors; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Controlled Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Retrospective Studies; Sex Factors; Treatment Outcome | 1998 |
Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dopamine; Haloperidol; Male; Microdialysis; Neostriatum; Norepinephrine; Nucleus Accumbens; Olanzapine; Pirenzepine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley | 1998 |
Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Fluorobenzenes; Haloperidol; Male; Nucleus Accumbens; Olanzapine; Piperidines; Pirenzepine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Time Factors | 1998 |
Conventional psychotropic-induced tremor extinguished by olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Fluphenazine; Haloperidol; Humans; Male; Mental Disorders; Olanzapine; Pirenzepine; Tremor | 1998 |
Olanzapine for primary negative symptoms.
Topics: Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Controlled Clinical Trials as Topic; Double-Blind Method; Haloperidol; Humans; Olanzapine; Pirenzepine; Research Design; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1998 |
Olanzapine for the treatment of tardive dyskinesia.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Biperiden; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Olanzapine; Pirenzepine; Schizophrenia; Substance Withdrawal Syndrome | 1998 |
Olanzapine-induced Fos expression in the rat forebrain; cross-tolerance with haloperidol and clozapine.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Corticosterone; Drug Tolerance; Haloperidol; Male; Olanzapine; Pirenzepine; Prosencephalon; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Time Factors | 1998 |
Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Corpus Striatum; Haloperidol; Infusion Pumps; Male; Microdialysis; Neurotensin; Nucleus Accumbens; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley; RNA, Messenger | 1998 |
Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Haloperidol; Imidazoles; Indoles; Male; Mastication; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley | 1998 |
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Life Tables; Male; Olanzapine; Pirenzepine; Psychotic Disorders; Randomized Controlled Trials as Topic; Recurrence; Schizophrenia; Survival Analysis; Treatment Outcome | 1998 |
Some, but not all, antipsychotic drugs potentiate a low level of prepulse inhibition shown by rats of the Wistar strain.
Topics: Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Behavior, Animal; Benzazepines; Benzodiazepines; Clozapine; Haloperidol; Imidazoles; Indoles; Injections, Intraperitoneal; Male; Neural Inhibition; Olanzapine; Pirenzepine; Prazosin; Rats; Rats, Wistar; Reflex, Startle; Remoxipride; Risperidone; Ritanserin; Serotonin Antagonists | 1997 |
Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Dopamine; Dopamine Agonists; Extracellular Space; Haloperidol; Male; Norepinephrine; Olanzapine; Piperazines; Pirenzepine; Prefrontal Cortex; Rats; Rats, Wistar; Reference Values; Risperidone; Tetrahydronaphthalenes; Thiazoles | 1998 |
Atypical neuroleptics enhance histamine turnover in brain via 5-Hydroxytryptamine2A receptor blockade.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Catalepsy; Clozapine; Drug Interactions; Haloperidol; Histamine; Histamine Antagonists; Imidazoles; Male; Methylhistamines; Mice; Olanzapine; Pirenzepine; Receptor, Serotonin, 5-HT2A; Receptors, Histamine H3; Receptors, Serotonin; Serotonin Antagonists | 1999 |
Body weight and leptin plasma levels during treatment with antipsychotic drugs.
Topics: Adipose Tissue; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Clozapine; Haloperidol; Hospitalization; Humans; Leptin; Mental Disorders; Olanzapine; Pirenzepine; Proteins; Weight Gain | 1999 |
[Neuroleptic malignant syndrome: case report with recurrence associated with the use of olanzapine].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Olanzapine; Pirenzepine; Recurrence | 1998 |
Complicated delirium in a cancer patient successfully treated with olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Olanzapine; Pirenzepine; Psychoses, Substance-Induced | 1999 |
A cost-effectiveness clinical decision analysis model for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; Decision Support Systems, Clinical; Haloperidol; Humans; Markov Chains; Olanzapine; Pirenzepine; Quality-Adjusted Life Years; Risperidone; Schizophrenia; Treatment Outcome; United States | 1998 |
Atypical antipsychotics and formulary decisions.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Drug Costs; Efficiency; Formularies as Topic; Haloperidol; Humans; Managed Care Programs; Olanzapine; Pirenzepine; Quality of Life; Schizophrenia; United States | 1998 |
Interaction between olanzapine and haloperidol.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Drug Interactions; Haloperidol; Humans; Male; Olanzapine; Parkinson Disease, Secondary; Pirenzepine | 1999 |
Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo.
Topics: 3T3 Cells; Animals; Antipsychotic Agents; Benzodiazepines; Cell Line; Clozapine; Dendrites; Fluorobenzenes; Haloperidol; Mianserin; Mice; Olanzapine; Piperidines; Pirenzepine; Prefrontal Cortex; Pyramidal Cells; Rats; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Recombinant Proteins; Risperidone; Ritanserin; Serotonin Antagonists; Transfection | 1999 |
Seizure associated with olanzapine.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Drug Interactions; Female; Haloperidol; Humans; Olanzapine; Phenytoin; Pirenzepine; Seizures | 1999 |
Stimulation of dopamine release in the bed nucleus of stria terminalis. A trait of atypical antipsychotics?
Topics: Amygdala; Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dopamine; Haloperidol; Indoles; Male; Olanzapine; Pirenzepine; Pyridines; Raclopride; Rats; Rats, Sprague-Dawley; Risperidone; Salicylamides; Thalamus | 1999 |
Effects of acute and chronic administration of olanzapine in comparison to clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons in the rat brain.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Haloperidol; Male; Neurons; Olanzapine; Pirenzepine; Rats; Rats, Wistar; Substantia Nigra | 1999 |
Differential effects of treatment with typical and atypical antipsychotic drugs on adenylyl cyclase and G proteins.
Topics: Adenylyl Cyclases; Animals; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Corpus Striatum; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Haloperidol; Male; Mice; Olanzapine; Pirenzepine | 1999 |
Dopamine D(3) receptors modulate evoked dopamine release from slices of rat nucleus accumbens via muscarinic receptors, but not from the striatum.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Dopamine; Dopamine Agonists; Dopamine Antagonists; Electric Stimulation; Haloperidol; In Vitro Techniques; Indans; Male; Muscarinic Antagonists; Neostriatum; Nucleus Accumbens; Pirenzepine; Quinpirole; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Muscarinic | 1999 |
Effects of atypical antipsychotic drugs vs. haloperidol on expression of heat shock protein in the discrete brain regions of phencyclidine-treated rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Corpus Striatum; Gene Expression Regulation; Gyrus Cinguli; Haloperidol; HSP70 Heat-Shock Proteins; Male; Nucleus Accumbens; Olanzapine; Phencyclidine; Pirenzepine; Prefrontal Cortex; Rats; Rats, Wistar; Risperidone; RNA, Messenger | 1999 |
A comparison of the acute effects of zotepine and other antipsychotics on rat cortical dopamine release, in vivo.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Dibenzothiepins; Dopamine; Fluoxetine; Frontal Lobe; Haloperidol; Male; Microdialysis; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Serotonin | 2000 |
Olanzapine. Keep an eye on this neuroleptic.
Topics: Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clinical Trials as Topic; Dopamine Antagonists; Double-Blind Method; Haloperidol; Humans; Olanzapine; Pirenzepine; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 2000 |
Effect of atypical antipsychotics on phencyclidine-induced expression of arc in rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cytoskeletal Proteins; Gene Expression; Haloperidol; Male; Nerve Tissue Proteins; Olanzapine; Phencyclidine; Pirenzepine; Rats; Rats, Wistar; Risperidone; RNA, Messenger; Tissue Distribution | 2000 |
Effects of antipsychotic drugs on metabolite ratios in rat brain in vivo.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aspartic Acid; Benzodiazepines; Brain; Choline; Clozapine; Creatine; Haloperidol; Magnetic Resonance Spectroscopy; Male; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley | 2000 |
The discriminative stimulus properties of the atypical antipsychotic olanzapine in rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Discrimination Learning; Generalization, Psychological; Haloperidol; Male; Olanzapine; Pirenzepine; Raclopride; Rats; Rats, Sprague-Dawley; Risperidone; Ritanserin; Scopolamine | 2000 |
Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex.
Topics: Action Potentials; Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dopamine; Haloperidol; Male; Neurons; Olanzapine; Pirenzepine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Ventral Tegmental Area | 2000 |
Olanzapine and tardive dyskinesia.
Topics: Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Pirenzepine; Psychotic Disorders | 1999 |
Effects of antipsychotic drugs on neurotoxicity, expression of fos-like protein and c-fos mRNA in the retrosplenial cortex after administration of dizocilpine.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Dizocilpine Maleate; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Haloperidol; Immunohistochemistry; In Situ Hybridization; Limbic System; Nervous System; Olanzapine; Pirenzepine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Risperidone; RNA, Messenger | 2000 |
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Drug Utilization; Female; Haloperidol; Humans; Male; Olanzapine; Pharmacoepidemiology; Pirenzepine; Practice Patterns, Physicians'; Prospective Studies; Risperidone; Schizophrenia | 2000 |
Restoration of latent inhibition by olanzapine but not haloperidol in entorhinal cortex-lesioned rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Entorhinal Cortex; Haloperidol; Inhibition, Psychological; Male; Olanzapine; Pirenzepine; Rats; Rats, Long-Evans; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2000 |
5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Chromatography, High Pressure Liquid; Clozapine; Corpus Striatum; Dopamine; Haloperidol; Male; Microdialysis; Olanzapine; Piperazines; Pirenzepine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Sensitivity and Specificity; Synaptic Transmission; Thiazoles; Time Factors | 2000 |
Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Costs and Cost Analysis; Haloperidol; Health Care Costs; Humans; Markov Chains; Models, Economic; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; United Kingdom | 2000 |
Subchronic treatment with either clozapine, olanzapine or haloperidol produces a hyposensitive response of the rat cortical cells to N-methyl-D-aspartate.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Synergism; Electrophysiology; Excitatory Amino Acid Agonists; Haloperidol; In Vitro Techniques; Male; N-Methylaspartate; Olanzapine; Pharmaceutical Vehicles; Pirenzepine; Prefrontal Cortex; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Time Factors | 2000 |
Effect of chronic olanzapine treatment on striatal synaptic organization.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Haloperidol; Male; Neostriatum; Olanzapine; Pirenzepine; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Synapses | 2001 |
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study.
Topics: Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Haloperidol; Humans; Olanzapine; Pirenzepine; Risperidone | 2000 |
Neuroleptic therapy influences basal ganglia activation: a functional magnetic resonance imaging study comparing controls to haloperidol- and olanzapine-treated inpatients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzodiazepines; Brain; Haloperidol; Hospitalization; Humans; Magnetic Resonance Imaging; Male; Olanzapine; Pirenzepine; Schizophrenia | 2000 |
Drug review "surprises" reader.
Topics: Aged; Alanine Transaminase; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Drug Interactions; Dyskinesia, Drug-Induced; Haloperidol; Humans; Liver; Middle Aged; Multicenter Studies as Topic; Olanzapine; Pirenzepine; Prolactin; Risk Factors; Safety; Schizophrenia | 2000 |
Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Corpus Striatum; Down-Regulation; Haloperidol; Imidazoles; Indoles; Male; Neurotransmitter Agents; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Thalamus; Up-Regulation | 2001 |
Reversal of rabbit syndrome with olanzapine.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Female; Haloperidol; Humans; Mouth Diseases; Olanzapine; Pirenzepine; Schizophrenia; Stereotypic Movement Disorder; Syndrome; Treatment Outcome | 2000 |
Repeated episodes of hypothermia in a subject treated with haloperidol, levomepromazine, olanzapine, and thioridazine.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Hypothermia; Methotrimeprazine; Olanzapine; Pirenzepine; Thioridazine | 2001 |
The economic consequences of a drug-drug interaction.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Depression; Drug Interactions; Female; Fluoxetine; Haloperidol; Health Care Costs; Humans; Olanzapine; Parkinson Disease; Pirenzepine; Selegiline; Trihexyphenidyl | 2001 |
Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Emergency Service, Hospital; Female; Haloperidol; Humans; Neuroleptic Malignant Syndrome; Olanzapine; Pirenzepine; Schizophrenia | 2001 |
Atypical antipsychotic drugs: how much better are they?
Topics: Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Haloperidol; Humans; Olanzapine; Pirenzepine | 2001 |
Dopamine receptor responsivity in schizophrenic patients in a drug-free state and after treatment with olanzapine.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Dopamine D2 Receptor Antagonists; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Prolactin; Receptors, Dopamine D2; Schizophrenia | 2001 |
Olanzapine in the treatment of tardive dyskinesia: a report of 2 cases.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Risperidone; Treatment Outcome | 2001 |
Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Binding Sites; Binding, Competitive; Cell Line; Clozapine; Dibenzothiazepines; Dopamine Antagonists; Haloperidol; Humans; Neurons; Norepinephrine; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Rats; Receptors, Adrenergic, alpha; Receptors, Dopamine; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Risperidone; Serotonin; Serotonin Antagonists; Thiazoles | 2001 |
Atypical neuroleptic drugs downregulate dopamine sensitivity in rat cortical and striatal astrocytes.
Topics: Adrenergic beta-Antagonists; Animals; Animals, Newborn; Antipsychotic Agents; Astrocytes; Benzodiazepines; Calcium; Calcium Signaling; Cells, Cultured; Cerebral Cortex; Clozapine; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Down-Regulation; Haloperidol; Intracellular Fluid; Neostriatum; Olanzapine; Pirenzepine; Rats; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D4; Risperidone; Serotonin Antagonists; Sulpiride | 2001 |
Extended treatment with typical and atypical antipsychotic drugs differential effects on the densities of dopamine D2-like and GABAA receptors in rat striatum.
Topics: Animals; Antipsychotic Agents; Benzamides; Benzazepines; Benzodiazepines; Chlorpromazine; Clozapine; Corpus Striatum; Dose-Response Relationship, Drug; Haloperidol; Male; Muscimol; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, GABA-A | 2001 |
Effects of acute versus chronic treatment with typical or atypical antipsychotics on d-amphetamine-induced sensorimotor gating deficits in rats.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Benzodiazepines; Central Nervous System Stimulants; Dextroamphetamine; Haloperidol; Hyperkinesis; Imidazoles; Indoles; Male; Olanzapine; Pirenzepine; Rats; Rats, Wistar; Receptors, Dopamine; Reflex, Startle; Time Factors | 2001 |
Increased responsiveness of dopamine to atypical, but not typical antipsychotics in the medial prefrontal cortex of rats reared in isolation.
Topics: Amino Acids; Animals; Antipsychotic Agents; Benzodiazepines; Chromatography, High Pressure Liquid; Clozapine; Dopamine; Excitatory Amino Acids; Haloperidol; Indicators and Reagents; Male; Microdialysis; Olanzapine; Pirenzepine; Prefrontal Cortex; Rats; Reflex, Startle; Social Isolation | 2001 |
Global index of safety (GIS): a new instrument to assess drug safety.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Benzodiazepines; Consumer Product Safety; Drug Monitoring; Haloperidol; Humans; Olanzapine; Pharmacoepidemiology; Pirenzepine; Risperidone; Schizophrenia | 2001 |
Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine.
Topics: Animals; Benzodiazepines; Binding, Competitive; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Guanosine 5'-O-(3-Thiotriphosphate); Guinea Pigs; Haloperidol; HeLa Cells; Humans; Ileum; In Vitro Techniques; Indoles; Lysergic Acid; Muscle Contraction; Olanzapine; Ondansetron; Pirenzepine; Quetiapine Fumarate; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Sulfur Radioisotopes; Tritium; Tropisetron | 2001 |
[Heart rate variability in schizophrenic patients treated with antipsychotic agents].
Topics: Adult; Antipsychotic Agents; Arrhythmias, Cardiac; Benzodiazepines; Clozapine; Female; Haloperidol; Heart Rate; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Schizophrenia | 2001 |
Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.
Topics: Adolescent; Adult; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cohort Studies; Drug Interactions; Female; Haloperidol; Humans; Male; Middle Aged; Netherlands; Olanzapine; Pirenzepine; Risk Factors; Risperidone | 2001 |
Acute administration of antipsychotics modulates Homer striatal gene expression differentially.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Carrier Proteins; Caudate Nucleus; Corpus Striatum; Disks Large Homolog 4 Protein; Enkephalins; Frontal Lobe; Haloperidol; Homer Scaffolding Proteins; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Nerve Tissue Proteins; Neuronal Plasticity; Neuropeptides; Nucleus Accumbens; Olanzapine; Parietal Lobe; Pirenzepine; Prefrontal Cortex; Putamen; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; RNA, Messenger | 2002 |
Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Cholinesterase Inhibitors; Clozapine; Corpus Striatum; Haloperidol; Male; Nucleus Accumbens; Olanzapine; Oxotremorine; Piperazines; Pirenzepine; Rats; Rats, Sprague-Dawley; Risperidone; Scopolamine; Sulpiride; Thiazoles; Thioridazine | 2002 |
Effects of antipsychotic drugs on operant responding after acute and repeated administration.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Conditioning, Operant; Dibenzothiazepines; Dose-Response Relationship, Drug; Haloperidol; Imidazoles; Indoles; Male; Olanzapine; Pirenzepine; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Remoxipride; Risperidone; Thioridazine; Time Factors | 2002 |
Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Mental Disorders; Olanzapine; Pirenzepine; Prospective Studies; Risperidone; Weight Gain | 2002 |
Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Dialysis Solutions; Dopamine Antagonists; Extracellular Space; Haloperidol; Hippocampus; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Microdialysis; Olanzapine; Piperazines; Pirenzepine; Rats; Rats, Wistar; Risperidone; Serotonin Antagonists; Thiazoles; Thioridazine | 2002 |
Subcortical overactivation in untreated schizophrenic patients: a functional magnetic resonance image finger-tapping study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzodiazepines; Brain; Brain Mapping; Female; Fingers; Haloperidol; Hospitalization; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Motor Activity; Olanzapine; Pirenzepine; Schizophrenia; Schizophrenic Psychology | 2002 |
Motor-induced brain activation in cortical, subcortical and cerebellar regions in schizophrenic inpatients. A whole brain fMRI fingertapping study.
Topics: Adult; Basal Ganglia; Benzodiazepines; Cerebellum; Cerebral Cortex; Female; Haloperidol; Humans; Linear Models; Magnetic Resonance Imaging; Male; Motor Skills; Olanzapine; Pirenzepine; Schizophrenia | 2002 |
Phencyclidine supersensitivity in rats with neonatal dopamine loss.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Animals, Newborn; Antipsychotic Agents; Benzazepines; Benzodiazepines; Corpus Striatum; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Female; Haloperidol; Ketamine; Male; Motor Activity; Olanzapine; Oxidopamine; Phencyclidine; Pirenzepine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; Sex Factors | 2002 |
Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Disease Models, Animal; Haloperidol; Hippocampus; Male; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley; Reflex, Startle; Reserpine; Schizophrenia | 2002 |
Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clomipramine; Clozapine; Haloperidol; Humans; Hypothalamo-Hypophyseal System; Male; Middle Aged; Olanzapine; Pirenzepine; Prolactin; Psychiatric Status Rating Scales; Receptors, Dopamine D2; Receptors, Serotonin; Schizophrenia; Treatment Outcome | 2002 |
Atypical neuroleptics stimulate neurogenesis in adult rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Brain Chemistry; Cell Differentiation; Haloperidol; Immunohistochemistry; Male; Olanzapine; Pirenzepine; Rats; Rats, Wistar; Risperidone | 2002 |
Effect of prenatal administration of haloperidol, risperidone, quetiapine and olanzapine on spatial learning and retention in adult rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Dibenzothiazepines; Drinking; Female; Haloperidol; Learning; Male; Olanzapine; Pirenzepine; Pregnancy; Prenatal Exposure Delayed Effects; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Retention, Psychology; Risperidone; Spatial Behavior | 2002 |
Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Child; Clozapine; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Prolactin; Psychotic Disorders; Schizophrenia | 2002 |
ECT treatment of malignant catatonia/NMS in an adolescent: a useful lesson in delayed diagnosis and treatment.
Topics: Adolescent; Benzodiazepines; Brain; Catatonia; Diagnosis, Differential; Diagnostic Imaging; Electroconvulsive Therapy; Electroencephalography; Female; Haloperidol; Humans; Neuroleptic Malignant Syndrome; Neurologic Examination; Neuropsychological Tests; Olanzapine; Pirenzepine; Treatment Outcome | 2002 |
[Improvement of tardive dyskinesia after treatment with olanzapine].
Topics: Affective Disorders, Psychotic; Aged; Benzodiazepines; Depressive Disorder, Major; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Neurologic Examination; Olanzapine; Paroxetine; Patient Admission; Pirenzepine | 2002 |
Decreased density of [3H]TCP binding following antipsychotic drug withdrawal in rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chlorpromazine; Clozapine; Haloperidol; Ion Channels; Male; Olanzapine; Phencyclidine; Pirenzepine; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substance Withdrawal Syndrome | 2002 |
Weight gain associated with atypical antipsychotics.
Topics: Adolescent; Benzodiazepines; Child; Dopamine Antagonists; Female; Haloperidol; Humans; Male; Obesity; Olanzapine; Pirenzepine; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Weight Gain | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Female; Haloperidol; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Olanzapine; Pirenzepine; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Risk Factors; Risperidone; Triglycerides; Weight Gain | 2002 |
Comparable dopamine 2 receptor occupancy.
Topics: Benzodiazepines; Cognition Disorders; Dopamine Antagonists; Haloperidol; Humans; Olanzapine; Pirenzepine; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors | 2002 |
Glucose intolerance with atypical antipsychotics.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Chlorpromazine; Clozapine; Diabetes Mellitus; Glucose Intolerance; Haloperidol; Humans; Hyperglycemia; Olanzapine; Pirenzepine; Risk Factors; Risperidone; World Health Organization | 2002 |
Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats.
Topics: Animals; Benzodiazepines; Brain; Choline O-Acetyltransferase; Cholinergic Fibers; Drug Administration Schedule; Escape Reaction; Haloperidol; Male; Maze Learning; Mental Recall; Microscopy, Fluorescence; Olanzapine; Orientation; Pirenzepine; Rats; Rats, Wistar; Reaction Time; Receptors, Cholinergic | 2002 |
Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic Factor; Clozapine; Dopamine Agents; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Hippocampus; In Situ Hybridization; Levodopa; Male; Olanzapine; Pirenzepine; Rats; Rats, Wistar; RNA, Messenger | 2003 |
Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents.
Topics: Adrenalectomy; Animals; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Clozapine; Corticosterone; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Gonadal Steroid Hormones; Haloperidol; Male; Olanzapine; Pirenzepine; Pregnanolone; Progesterone; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Risperidone | 2003 |
Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Cognition Disorders; Female; Haloperidol; Humans; Male; Olanzapine; Patient Compliance; Pirenzepine; Risperidone; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2002 |
Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepines; Female; Haloperidol; Humans; Leptin; Male; Olanzapine; Pirenzepine; Quetiapine Fumarate; Schizophrenia; Triglycerides; Weight Gain | 2003 |
alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brimonidine Tartrate; Chlorpromazine; CHO Cells; Clozapine; Cricetinae; Cyclic AMP; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Humans; Isoxazoles; Norepinephrine; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quetiapine Fumarate; Quinolones; Quinoxalines; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D2; Risperidone; Thiazoles; Transfection; Yohimbine | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Research Design; Risperidone; Schizophrenia; Treatment Outcome | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Pirenzepine; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Risperidone; Schizophrenia; Treatment Outcome | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Pirenzepine; Research Design; Research Support as Topic; Risperidone; Schizophrenia; Treatment Outcome | 2003 |
Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation.
Topics: Analgesics; Animals; Antipsychotic Agents; Autoradiography; Benzodiazepines; Brain; Clozapine; Deoxyglucose; Drug Interactions; Haloperidol; Ketamine; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley | 2003 |
Olanzapine and clozapine but not haloperidol reverse subchronic phencyclidine-induced functional hyperactivity of N-methyl-D-aspartate receptors in pyramidal cells of the rat medial prefrontal cortex.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Excitatory Amino Acid Agonists; Haloperidol; Male; Membrane Potentials; N-Methylaspartate; Olanzapine; Patch-Clamp Techniques; Phencyclidine; Pirenzepine; Prefrontal Cortex; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Schizophrenia | 2003 |
Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Estrogens; Female; Haloperidol; Humans; Hyperprolactinemia; Male; Olanzapine; Pirenzepine; Prolactin; Risk Factors; Risperidone; Schizophrenia; Sex Characteristics | 2003 |
Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Drinking Behavior; Eating; Fat Emulsions, Intravenous; Feeding Behavior; Haloperidol; Male; Movement; Olanzapine; Pirenzepine; Rats; Time Factors; Tongue | 2003 |
Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapine and tiapride.
Topics: Aged; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Olanzapine; Pirenzepine; Tetrabenazine; Tiapamil Hydrochloride; Treatment Outcome | 2003 |
Role of ethnicity in predicting antipsychotic medication adherence.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Ethnicity; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Patient Compliance; Pirenzepine; Risperidone; Schizophrenia | 2003 |
Cells in midline thalamus, central amygdala, and nucleus accumbens responding specifically to antipsychotic drugs.
Topics: Amygdala; Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Diphenhydramine; Haloperidol; Immunohistochemistry; Injections, Intraperitoneal; Lorazepam; Male; Midline Thalamic Nuclei; Nucleus Accumbens; Olanzapine; Pirenzepine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley | 2003 |
Comparison of the effects of antipsychotics on a delayed radial maze task in the rat.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Dose-Response Relationship, Drug; Food Deprivation; Haloperidol; Male; Maze Learning; Memory; Olanzapine; Piperazines; Pirenzepine; Rats; Rats, Sprague-Dawley; Risperidone; Thiazoles | 2003 |
Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Brain-Derived Neurotrophic Factor; Dizocilpine Maleate; Dose-Response Relationship, Drug; Down-Regulation; Excitatory Amino Acid Antagonists; Glutamic Acid; Haloperidol; Male; Neuronal Plasticity; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Schizophrenia; Synaptic Transmission | 2003 |
Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Diet; Disease Models, Animal; Dose-Response Relationship, Drug; Drinking; Eating; Female; Food Preferences; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Rats; Rats, Wistar; Sex Characteristics; Weight Gain | 2003 |
Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Spain; Weight Gain | 2003 |
A comparison of drug effects in latent inhibition and the forced swim test differentiates between the typical antipsychotic haloperidol, the atypical antipsychotics clozapine and olanzapine, and the antidepressants imipramine and paroxetine.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Clozapine; Conditioning, Psychological; Haloperidol; Imipramine; Inhibition, Psychological; Male; Models, Animal; Olanzapine; Paroxetine; Pirenzepine; Rats; Rats, Wistar; Swimming | 2003 |
Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Corpus Striatum; Cyclic GMP; Dyskinesia, Drug-Induced; Haloperidol; Male; Mastication; Nitric Oxide; Nitric Oxide Synthase; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley | 2003 |
Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Black or African American; Drug Utilization; Female; Haloperidol; Hispanic or Latino; Humans; Logistic Models; Male; Medicaid; Middle Aged; Olanzapine; Pirenzepine; Schizophrenia; Texas; White People | 2003 |
Alpha2-adrenoceptor antagonism is neither sufficient nor necessary for the distinctive action of atypical neuroleptics on intracranial self-stimulation in the rat.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Clonidine; Haloperidol; Idazoxan; Male; Motivation; Olanzapine; Pirenzepine; Rats; Receptors, Adrenergic, alpha-2; Self Stimulation | 2003 |
Rehospitalization risk with second-generation and depot antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Data Collection; Delayed-Action Preparations; Female; Fluphenazine; Haloperidol; Humans; Male; Olanzapine; Patient Readmission; Pirenzepine; Risperidone; Schizophrenia; Secondary Prevention; Time Factors; Treatment Outcome | 2003 |
Bilateral lesions of the entorhinal cortex differentially modify haloperidol- and olanzapine-induced c-fos mRNA expression in the rat forebrain.
Topics: Animals; Benzodiazepines; Entorhinal Cortex; Gene Expression Regulation; Genes, fos; Haloperidol; Male; Olanzapine; Pirenzepine; Prosencephalon; Rats; Rats, Long-Evans; RNA, Messenger | 2003 |
Antipsychotic drugs differentially modulate apolipoprotein D in rat brain.
Topics: Animals; Antipsychotic Agents; Apolipoproteins; Apolipoproteins D; Benzodiazepines; Brain; Haloperidol; Male; Neuronal Plasticity; Neurons; Olanzapine; Pirenzepine; Rats; Rats, Wistar; Risperidone | 2003 |
[Neuroleptics and cognition].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Pirenzepine; Product Surveillance, Postmarketing; Risperidone; Schizophrenia; Schizophrenic Psychology | 2003 |
Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Brain Injuries; Cognition Disorders; Dopamine Antagonists; Dose-Response Relationship, Drug; Haloperidol; Injections, Intraperitoneal; Male; Maze Learning; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley; Swimming | 2003 |
[Fast control of manic or mixed episodes. Atypical neuroleptics for bipolar patients].
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Dopamine Antagonists; Drug Therapy, Combination; Haloperidol; Humans; Isotopes; Lithium; Olanzapine; Pirenzepine; Selective Serotonin Reuptake Inhibitors; Time Factors; Valproic Acid | 2003 |
Similarities and differences among antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2003 |
Effects of typical and atypical antipsychotic drugs on rat brain muscarinic receptors.
Topics: Animals; Antidepressive Agents, Second-Generation; Brain; Clozapine; Female; Haloperidol; Organ Specificity; Pirenzepine; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Reference Values | 2007 |
Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol.
Topics: Amphetamine; Animals; Antipsychotic Agents; Central Nervous System Stimulants; Clozapine; DNA Primers; Haloperidol; Male; Muscarinic Antagonists; Pirenzepine; Rats; Rats, Sprague-Dawley; Receptor, Muscarinic M1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Schizophrenia; Schizophrenic Psychology | 2008 |
The potency and efficacy of anticholinergics to inhibit haloperidol-induced catalepsy in rats correlates with their rank order of affinities for the muscarinic receptor subtypes.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Catalepsy; Cholinergic Antagonists; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; Male; Pirenzepine; Protein Binding; Rats; Rats, Wistar; Reaction Time; Receptors, Muscarinic; Time Factors | 2014 |